DAILY MORNING NOTE | 25 August 2026

Singapore stocks ended lower on Monday (Aug 24). The benchmark lost 0.1 per cent or 8.50 points to finish at 5,680.46. Wilmar International led the gainers on Singapore’s blue-chip index, rising 1.3 per cent or S$0.05 to S$3.76. The worst performer was Seatrium, which fell 2.8 per cent or S$0.06 to S$2.09.

The S&P 500 and Nasdaq ended lower on Monday (Aug 24), pulled down by technology stocks, as investors weighed fresh US economic pressure against Iran and braced for a week that includes Nvidia earnings and a closely watched inflation report. In the US, the S&P fell 0.3% to 7,652.86, the Dow Jones gained 0.3% to 53,417.16, and the NASDAQ declined 0.8% to 25,980.19.


Singapore Technical Highlights

Factsheets


TOP 5 GAINERS & LOSERS

Factsheets


EVENTS OF THE WEEK

Factsheets


SG

UOB‘s damages award against developer Lippo Marina Collection more than quadrupled to S$76.1 million from S$17.7 million after the Appellate Division ruled in favour of its appeal over fraudulently inflated housing loans disbursed between 2011 and 2013.

UltraGreen.ai said it will calibrate its commercial response to new US competitors based on their pricing and distribution, with CEO noting FDA approval of rivals does not indicate commercial launch; shares rose 13.4% to US$0.72.

Sheffield Green‘s Taiwan branch is under investigation by Kaohsiung City Labour Affairs Bureau over alleged discrepancies between actual work and job descriptions in two Indonesian employees’ contracts; expects no material impact on FY results.

UG Healthcare expects to report a net profit for 2HFY2026 and FY2026 ended June 30, reversing losses in the year-earlier periods, citing higher sales volume and average selling price of disposable gloves and improved operational efficiency.

OUE Healthcare unit proposes to privatise at S$0.05 per share scheme deal. The price offers a 28.2% premium over the last transacted share price of S$0.039 on Aug 21

First REIT completion of proposed divestment is expected to take place on October 2026 subjected to approval by Siloam. An EGM will be held on September 2026 to seek approval. Siloam group have granted the Put Options to members of the First REIT Group in relation to the potential divestment of their equity interests in six hospital assets in the First REIT Group’s Indonesia portfolio. The put options exercise period expires on 31 October 2026 or 31 December 2026.


US

Nvidia is in talks to invest in AI startup Perplexity as part of an equity funding round that would value the company at more than US$30 billion, up more than 50 per cent from its 2025 financing. Nvidia has also announced its Groq 3 LPX chip is in full production, marking the commercialization of technology from the company’s largest-ever acquisition of USD 20 billion. Groq rack will be deployed alongside Vera Central processors and Rubin graphics processors at neocloud Nebius and will be online later this year.

Micron Technology Inc. CEO Sanjay Mehrotra said memory supply shows no sign of catching up with artificial intelligence-driven demand, citing long-term customer agreements locking in years of committed supply as evidence that the current boom is structural, not cyclical.

Bank of America executives held talks with Syria’s finance minister over potential cooperation and Syria’s reintegration into the international financial system following US removal of Syria from its terrorism sponsor list.

Johnson & Johnson’s multiple myeloma treatment secures EC approval. The approval is based on findings from the ongoing Phase III MajesTEC-3 study involving patients with refractory multiple Myeloma.

Ford fell 3.3 per cent after President Trump warned tariffs on cars, trucks and automotive parts from Canada would be increased to 50 per cent starting Jan 1.

Goldman Sachs partner Chris Churchman, who leads the Marquee digital platform for institutional clients, warned that AI could cause “cognitive atrophy” by replacing bankers’ reasoning skills, while noting the firm hasn’t yet figured out how to balance AI with human involvement.

Source: SGX Masnet, Bloomberg, Channel NewsAsia, Reuters, CNBC, WSJ, The Business Times, The Edge Singapore, PSR


RESEARCH REPORTS


Market Journal articles powered by PhillipGPT

Prime US REIT Shows Recovery Momentum with Occupancy Gains, Maintains US$0.25 Target Price & Buy Rating

United Hampshire US REIT Posts Solid Growth with Strong Defensive Portfolio, Maintains Buy Rating at US$0.69 Target

PopNex Market Share Advances Despite Challenging New Home Sales Environment, Maintains S$2.08 Target Price & Accumulate Rating


PSR Stocks Coverage

Factsheets


For more information, please visit:

https://www.stocksbnb.com/singapore-stocks-coverage/


HK Reports

Read up on our Hong Kong reports here

Upcoming Webinars

Corporate Insights by Keppel REIT

Date & Time: 25 August 26 | 12PM-1PM

Register: poems-20260825-152077


Corporate Insights by Micro-Mechanics

Date & Time: 27 August 26 | 12PM-1PM

Register: poems-20260827-152848


Corporate Insights by ComfortDelGro [NEW]

Date & Time: 10 September 26 | 12PM-1PM

Register: poems-20260910-153422


POEMS Podcast:

Research Videos

Weekly Market Outlook: Nordic Group, Lendlease, Ultragreen.ai, CDL,ABNB,PLTR, SE, SHOP & More!
Date: 17 August 2026

Click here for more on Market Outlook.
Sign up for our webinars here, and be among the first to receive economy and market updates.

PHILLIP RESEARCH IN 3 MINS

Follow our Socials

Facebook Social Icon Instagram Icon Twitter Social Icon Youtube Social Icon Linkedin Social Icon TikTok Social Icon Spotify Social Icon

Join our Singapore Equity Research Community on POEMS Mobile 3 App for the latest research reports, market updates, insights and more

Click to join!

Disclaimer

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.

Confidentiality Note

This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com